Episode 3: Mesenchymal stem cells for COVID-19 treatment
Release Date:
Mesoblast CEO Dr. Silviu Itescu speaks to Lonza about the company’s advanced portfolio of anti-inflammatory allogeneic cellular medicines including remestemcel-L, which is currently being evaluated in a U.S. Phase 3 randomized controlled trial for acute respiratory distress syndrome (ARDS), the principal cause of mortality due to COVID-19 infection.
Episode 3: Mesenchymal stem cells for COVID-19 treatment